Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Item
http://www.wikidata.org/entity/Q30224832
Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolatesA Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-AnalysisOutbreak of pyrazinamide-monoresistant tuberculosis identified using genotype cluster and social media analysis.The pyrazinamide susceptibility breakpoint above which combination therapy fails.Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistanceEvaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide.Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in ChinaClinical Impact on Tuberculosis Treatment Outcomes of Discordance Between Molecular and Growth-Based Assays for Rifampin Resistance, California 2003-2013.Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.Association between pncA gene mutations, pyrazinamidase activity, and pyrazinamide susceptibility testing in Mycobacterium tuberculosis.Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum.Non-pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That?Using Reduced Inoculum Densities of Mycobacterium tuberculosis in MGIT Pyrazinamide Susceptibility Testing to Prevent False-Resistant Results and Improve Accuracy: A Multicenter Evaluation.
P2860

Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Item
http://www.wikidata.org/entity/Q30224832
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Reevaluation of the critical c ...... ions and pncA gene sequencing.
@ast
Reevaluation of the critical c ...... ions and pncA gene sequencing.
@en
type
label
Reevaluation of the critical c ...... ions and pncA gene sequencing.
@ast
Reevaluation of the critical c ...... ions and pncA gene sequencing.
@en
prefLabel
Reevaluation of the critical c ...... ions and pncA gene sequencing.
@ast
Reevaluation of the critical c ...... ions and pncA gene sequencing.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P932
P356
P1433
P1476
Reevaluation of the critical c ...... ions and pncA gene sequencing.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P932